JP2020536121A - 駆出率が保持された心不全を治療する方法 - Google Patents

駆出率が保持された心不全を治療する方法 Download PDF

Info

Publication number
JP2020536121A
JP2020536121A JP2020539153A JP2020539153A JP2020536121A JP 2020536121 A JP2020536121 A JP 2020536121A JP 2020539153 A JP2020539153 A JP 2020539153A JP 2020539153 A JP2020539153 A JP 2020539153A JP 2020536121 A JP2020536121 A JP 2020536121A
Authority
JP
Japan
Prior art keywords
imegrimin
patient
day
administered
hfpef
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020539153A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020536121A5 (enExample
Inventor
アラクウ−ボゼック ソフィー
アラクウ−ボゼック ソフィー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Poxel SA
Original Assignee
Poxel SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Poxel SA filed Critical Poxel SA
Publication of JP2020536121A publication Critical patent/JP2020536121A/ja
Publication of JP2020536121A5 publication Critical patent/JP2020536121A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020539153A 2017-10-02 2018-10-02 駆出率が保持された心不全を治療する方法 Pending JP2020536121A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762566668P 2017-10-02 2017-10-02
US62/566,668 2017-10-02
PCT/IB2018/057648 WO2019069230A1 (en) 2017-10-02 2018-10-02 METHODS OF TREATING CARDIAC INSUFFICIENCY WITH PRESERVED EJECTION FRACTION

Publications (2)

Publication Number Publication Date
JP2020536121A true JP2020536121A (ja) 2020-12-10
JP2020536121A5 JP2020536121A5 (enExample) 2021-12-02

Family

ID=63963334

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020539153A Pending JP2020536121A (ja) 2017-10-02 2018-10-02 駆出率が保持された心不全を治療する方法

Country Status (12)

Country Link
US (1) US11617754B2 (enExample)
EP (1) EP3691650A1 (enExample)
JP (1) JP2020536121A (enExample)
KR (1) KR20200102982A (enExample)
CN (1) CN111163782A (enExample)
BR (1) BR112020006472A2 (enExample)
CA (1) CA3078163A1 (enExample)
IL (1) IL273723A (enExample)
MX (1) MX2020003243A (enExample)
TW (1) TW201924689A (enExample)
WO (1) WO2019069230A1 (enExample)
ZA (1) ZA202002292B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019069230A1 (en) 2017-10-02 2019-04-11 Poxel METHODS OF TREATING CARDIAC INSUFFICIENCY WITH PRESERVED EJECTION FRACTION
TWI846700B (zh) 2018-06-06 2024-07-01 瑞士商梅萬特科學公司 治療患有慢性腎臟病之糖尿病患者之方法
MX2020013567A (es) 2018-06-14 2021-05-27 Poxel Tableta recubierta con pelicula que comprende un derivado de triazina para su uso en el tratamiento de la diabetes.
CN115770062B (zh) * 2021-09-07 2025-10-10 深圳迈瑞生物医疗电子股份有限公司 一种超声波数据的处理方法、成像装置
CN116440075B (zh) * 2023-06-01 2025-05-06 苏州中化药品工业有限公司 一种干混悬剂及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017507956A (ja) * 2014-02-28 2017-03-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｐｐ−４阻害薬の医学的使用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2804113B1 (fr) 2000-01-26 2004-06-18 Lipha Derives animes de dihydro-1,3,5-triazine et leurs applications en therapeutique
FR2853650B1 (fr) 2003-04-10 2006-07-07 Merck Sante Sas Procede de dedoublement d'amines utiles pour le traitement de desordres associes au syndrome d'insulino-resistance
FR2896161B1 (fr) 2006-01-13 2008-04-04 Merck Sante Soc Par Actions Si Utilisation de derives de triazines pour fabriquer un medicament ayant un effet cicatrisant ou angiogenique.
FR2896159B1 (fr) 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents sensibilisateurs a l'insuline.
FR2896157B1 (fr) 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline.
DE102008007314A1 (de) 2008-02-02 2009-08-06 Merck Patent Gmbh Verfahren zur Herstellung von 3,6-Dihydro-1,3,5-triazinderivaten
PL2300444T3 (pl) 2008-05-23 2016-08-31 Poxel Sas Sposób syntezy pochodnych 3,6-dihydro-1,3,5-triazyny
SI2344435T1 (sl) 2008-07-29 2016-05-31 Poxel Proces izolacije enantiomernih spojin iz enantiomernih mešanic s kristalizacijo nadzorovano z velikostjo delcev
CN102245581A (zh) 2008-12-12 2011-11-16 普克塞尔公司 用于治疗与ampk活性有关的疾病的四氢三嗪化合物
ES2530223T3 (es) 2008-12-12 2015-02-27 Poxel S.A.S. Combinación de insulina con derivados de triazina y su uso para tratar la diabetes
WO2010109015A1 (en) 2009-03-26 2010-09-30 Poxel Process for enantiomeric separation of racemic dihydro-1,3,5 triazines via preferential crystallization
FR2948027A1 (fr) * 2009-07-17 2011-01-21 Merck Sante Sas Derives amines de dihydro-1,3,5-triazine pour leur utilisation dans le traitement des maladies associees a une ischemie et/ou une reperfusion
WO2011154496A1 (en) 2010-06-09 2011-12-15 Poxel Treatment of type 1 diabetes
TWI436768B (zh) * 2010-06-09 2014-05-11 Poxel 第２型糖尿病之治療
JP5758010B2 (ja) 2010-12-01 2015-08-05 ポクセルＰｏｘｅｌ 酒石酸によるトリアジン誘導体エナンチオマーの分離
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
US20160151461A1 (en) * 2013-03-14 2016-06-02 The Trustees Of The University Of Pennsylvania Cardio-Metabolic and Vascular Effects of GLP-1 Metabolites
CA2812519A1 (en) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
WO2016077126A1 (en) 2014-11-10 2016-05-19 Merck Sharp & Dohme Corp. Sglt-2 inhibitors for treating metabolic disorders in patients with renal impairment or chronic kidney disease
MA43709A (fr) * 2016-03-16 2018-11-28 Boehringer Ingelheim Int Composition pharmaceutique comprenant de l'empagliflozine et ses utilisations
WO2019069230A1 (en) 2017-10-02 2019-04-11 Poxel METHODS OF TREATING CARDIAC INSUFFICIENCY WITH PRESERVED EJECTION FRACTION
TWI846700B (zh) 2018-06-06 2024-07-01 瑞士商梅萬特科學公司 治療患有慢性腎臟病之糖尿病患者之方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017507956A (ja) * 2014-02-28 2017-03-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｐｐ−４阻害薬の医学的使用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
J CLIN MED RES, vol. 10, no. 11, JPN6022030872, 2018, pages 799 - 805, ISSN: 0004838526 *
LACHAUX M; ET AL: "P577 | BENCH: SHORT- AND LONG-TERM IMEGLIMIN TREATMENT REDUCES METABOLIC SYNDROME-RELATED DIABETIC C", EUROPEAN HEART JOURNAL, vol. VOL:38, NR:SUPPL1, JPN5021001821, 29 August 2017 (2017-08-29), GB, pages 101, ISSN: 0005043412 *
LACHAUX, MARIANNE ET AL.: "Short- and long-term imeglimin treatment reduces metabolic syndrome-related diabetic cardiomyopathy", EASD (EUROPEAN ASSOCIATION FOR THE STUDY OF DIABETES) [ONLINE], JPN6022030875, August 2017 (2017-08-01), ISSN: 0005043413 *

Also Published As

Publication number Publication date
CN111163782A (zh) 2020-05-15
CA3078163A1 (en) 2019-04-11
US11617754B2 (en) 2023-04-04
ZA202002292B (en) 2022-12-21
WO2019069230A1 (en) 2019-04-11
IL273723A (en) 2020-05-31
TW201924689A (zh) 2019-07-01
MX2020003243A (es) 2020-09-18
US20200316078A1 (en) 2020-10-08
BR112020006472A2 (pt) 2020-10-06
EP3691650A1 (en) 2020-08-12
KR20200102982A (ko) 2020-09-01

Similar Documents

Publication Publication Date Title
Matyas et al. Chronic plus binge ethanol feeding induces myocardial oxidative stress, mitochondrial and cardiovascular dysfunction, and steatosis
JP2020536121A (ja) 駆出率が保持された心不全を治療する方法
Oudegeest-Sander et al. The effect of an advanced glycation end-product crosslink breaker and exercise training on vascular function in older individuals: a randomized factorial design trial
Oláh et al. Physiological and pathological left ventricular hypertrophy of comparable degree is associated with characteristic differences of in vivo hemodynamics
US10792280B2 (en) Pharmaceutical composition comprising amodiaquine and anti-diabetes drug as effective ingredient for prevention or treatment of diabetes
Larson et al. Cardiac reactive oxygen species after traumatic brain injury
Levy et al. Evaluating myocardial depression in sepsis
Abdesselam et al. Time course of cardiometabolic alterations in a high fat high sucrose diet mice model and improvement after GLP-1 analog treatment using multimodal cardiovascular magnetic resonance
Ahmed et al. Naringenin adds to the protective effect of l-arginine in monocrotaline-induced pulmonary hypertension in rats: Favorable modulation of oxidative stress, inflammation and nitric oxide
Alhumaid et al. A contemporary review of the effects of exercise training on cardiac structure and function and cardiovascular risk profile: insights from imaging
JP2008527003A (ja) 喘息又は気管支痙攣の既往歴を有する患者における心筋機能不全を検出する方法
Carrick-Ranson et al. Effects of aging and endurance exercise training on cardiorespiratory fitness and cardiac structure and function in healthy midlife and older women
WO2024255256A1 (zh) 丙酮酸脱氢酶激酶抑制剂在治疗射血分数保留型心力衰竭中的应用
HK40022791A (en) Methods of treating heart failure with preserved ejection fraction
US20160067246A1 (en) Use of phosphodiesterase 5a inhibitors for the treatment of muscular dystrophy
Suzuki et al. Comparative effect of carperitide and furosemide on left atrial pressure in dogs with experimentally induced mitral valve regurgitation
Azza et al. Echocardiographic assessment of epicardial adipose tissue in obese children and its relation to clinical parameters of the metabolic syndrome
US20230060177A1 (en) Method for treating athletes subject to pathological cardiac hypertrophy by administering nigella sativa
Park et al. Echocardiographic assessment of coronary artery flow in normal canines and model dogs with myocardial infarction
NOORI et al. The Correlation of Ferritin and Leptin Serum Levels with Cardiac Involvement in Thalassemia Patients Compared to Controls
Kuang et al. Sacubitril/valsartan increased survival via inhibiting inflammation and myocardiofibrosis in Takotsubo-like cardiomyopathy
EL-Farook et al. The Effect of Metabolic Syndrome on Systolic Function of Left Ventricle Using Echocardiographic Examination
CN118434418A (zh) 用于改善心脏功能的组合物
CN116966176A (zh) 脂肪酸结合蛋白4抑制剂在治疗射血分数保留型心力衰竭中的应用
Mpharm et al. Free fatty acid availability is closely related to myocardial lipid storage and cardiac function in hypoglycemia counter-regulation 2

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20201211

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20201215

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210910

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211020

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220720

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220801

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221014

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230119

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230424